Cytokinetics CYTK Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's other income (expense)?
- Cytokinetics (CYTK) reported other income (expense) of $11.02M in Q1 2026.
- How has Cytokinetics's other income (expense) changed year-over-year?
- Cytokinetics's other income (expense) decreased by 19.6% year-over-year, from $13.7M to $11.02M.
- What is the long-term trend for Cytokinetics's other income (expense)?
- Over 3 years (2022 to 2025), Cytokinetics's other income (expense) has grown at a 62.2% compound annual growth rate (CAGR), from $11.34M to $48.42M.
- What does other income (expense) mean?
- Net income or loss from activities outside of core business operations.
- How do you interpret other income (expense)?
- Positive values provide a boost to net income, while negative values act as a drag on overall financial performance.
- How does other income (expense) compare across companies?
- Highly variable across companies depending on treasury management and non-core asset holdings.